Legal analysis of four hypothetical scenarios for prescribing buprenorphine for opioid use disorder in the United States during the novel coronavirus outbreak.
Details concerning the additional challenges faced by the SUD (and OUD) population at this time, the positive ameliorative steps taken by federal, state, and local governments, and recommended additional steps that are needed.
Join Jocelyn Guyer, MPA, and Jodi Manz, MSW, as they review emerging federal and state actions and opportunities (including case studies) to assist those with OUD through the COVID-19 pandemic.
The Substance Abuse and Mental Health Services Administration (SAMHSA) is providing guidance to ensure that SUD treatment services are uninterrupted during the COVID-19 public health emergency.
Join Dr. Hannah Snyder, Jodi Manz, MSW, and Daniel McClughen, Esq. as they review key steps, fast evolving regulatory changes, and newly issued guidance around MOUD during the COVID-19 pandemic.
The Substance Abuse and Mental Health Services Administration (SAMHSA) has compiled an FAQ on prescribing MOUD during the COVID-19 pandemic.